Pliant Historical Cash Flow
| PLRX Stock | USD 13.46 0.48 3.70% |
Analysis of Pliant Therapeutics cash flow over time is an excellent tool to project Pliant Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Change To Account Receivables of 2.1 M or Change To Operating Activities of 6.7 M as it is a great indicator of Pliant Therapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Pliant Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Pliant Therapeutics is a good buy for the upcoming year.
Pliant |
About Pliant Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Pliant balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Pliant's non-liquid assets can be easily converted into cash.
Pliant Therapeutics Cash Flow Chart
Add Fundamental
Capital Expenditures
Capital Expenditures are funds used by Pliant Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Pliant Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from Pliant Therapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Pliant Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pliant Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Pliant Stock please use our How to Invest in Pliant Therapeutics guide.At this time, Pliant Therapeutics' Begin Period Cash Flow is fairly stable compared to the past year.
| 2021 | 2022 | 2023 | 2024 (projected) | Capital Expenditures | 2.0M | 1.8M | 921K | 1.2M | Depreciation | 1.5M | 1.8M | 1.8M | 1.3M |
Pliant Therapeutics cash flow statement Correlations
Click cells to compare fundamentals
Pliant Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Pliant Therapeutics cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Sale Purchase Of Stock | 48.1M | 213.2M | 2.5M | 215.6M | 248.0M | 260.4M | |
| Change In Cash | 24.9M | (34.9M) | 783K | (18.0M) | 31.0M | 32.6M | |
| Total Cashflows From Investing Activities | (17.9M) | (210.9M) | 73.7M | (150.2M) | (135.2M) | (128.4M) | |
| Other Cashflows From Financing Activities | 45.5M | 52.0M | (457K) | 216.9M | (847K) | (804.7K) | |
| Depreciation | 1.1M | 1.3M | 1.5M | 1.8M | 1.8M | 1.3M | |
| Capital Expenditures | 964K | 1.5M | 2.0M | 1.8M | 921K | 1.2M | |
| Total Cash From Operating Activities | (2.8M) | (37.3M) | (75.4M) | (94.6M) | (116.4M) | (110.5M) | |
| Change To Operating Activities | 3.1M | (154K) | (1.3M) | 5.6M | 6.4M | 6.7M | |
| Net Income | (631K) | (41.5M) | (97.3M) | (123.3M) | (161.3M) | (153.3M) | |
| Total Cash From Financing Activities | 45.5M | 213.2M | 2.5M | 226.9M | 274.4M | 288.1M | |
| End Period Cash Flow | 85.8M | 50.9M | 51.7M | 33.7M | 64.7M | 55.3M | |
| Change To Netincome | 1.8M | 4.2M | 10.4M | 22.6M | 26.0M | 27.3M | |
| Change To Liabilities | (1.1M) | 1.2M | 3.6M | 6.6M | 7.5M | 7.9M | |
| Stock Based Compensation | 1.8M | 3.9M | 10.4M | 22.6M | 44.5M | 46.7M | |
| Free Cash Flow | (3.7M) | (38.8M) | (77.4M) | (96.4M) | (117.3M) | (111.4M) | |
| Change In Working Capital | (5.1M) | (1.2M) | 6.9M | 4.2M | 1.3M | 1.3M | |
| Begin Period Cash Flow | 60.9M | 85.8M | 50.9M | 51.7M | 33.7M | 52.7M | |
| Issuance Of Capital Stock | 47.9M | 212.8M | 3.0M | 217.6M | 275.1M | 154.7M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Pliant Stock Analysis
When running Pliant Therapeutics' price analysis, check to measure Pliant Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pliant Therapeutics is operating at the current time. Most of Pliant Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pliant Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pliant Therapeutics' price. Additionally, you may evaluate how the addition of Pliant Therapeutics to your portfolios can decrease your overall portfolio volatility.